FindTrial
Sign In

Antibody-Drug Conjugate

DRUG4 trials

Sponsors

Central South University, MBrace Therapeutics, Sung-Soo Park

Conditions

AgranulocytosisBurkitt LymphomaCancerDiffuse Large B Cell Lymphoma RelapsedHigh Grade B-cell LymphomaMultiple Myeloma (MM)Multiple Myeloma, RelapsedOpportunistic Infections

Phase 1

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RecruitingNCT06014658
MBrace TherapeuticsCancer
Start: 2023-11-07End: 2026-11-01Target: 130Updated: 2026-03-02

Unknown Phase

Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities
CompletedNCT05349383
Central South UniversityAgranulocytosis, Opportunistic Infections, Sepsis (SMQ)
Start: 2022-04-22End: 2022-06-01Updated: 2022-06-22
Immunotherapy in Lymphoma
RecruitingNCT06796517
Sung-Soo ParkBurkitt Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, High Grade B-cell Lymphoma +2
Start: 2024-06-26End: 2025-12-31Target: 72Updated: 2025-01-28
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
RecruitingNCT07051850
Sung-Soo ParkMultiple Myeloma (MM), Multiple Myeloma, Relapsed
Start: 2025-07-14End: 2025-12-31Target: 174Updated: 2025-07-15

Related Papers

First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors
Journal of Clinical Investigation2025-07-14
A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid tumors.
Journal of Clinical Oncology2024-06-01
Abstract 738: MBRC-101: a novel antibody-drug conjugate (ADC) targeting the tyrosine kinase receptor EphA5
Cancer Research2024-03-221 citations